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 Many natural products, including fatty acids, polyketides, and non-
ribosomal peptides have pharmacologically valuable properties. These 
products are biosynthesized using diverse pathways, but they employ very 
similar machineries and chemical transformations. Central to these 
pathways are carrier proteins, which covalently tether a growing 
intermediate. Small, dynamic carrier proteins facilitate transport of 
  
 
xxv 
intermediates to subsequent reaction partners within the biosynthetic 
pathway, and protect them from unfavorable reactions in the cytosol. This 
dissertation focuses on these carrier proteins, characterizing them both 
structurally and biophysically. Solution state protein NMR methods are 
ideal for studying carrier proteins, given their small size and high flexibility. 
Several studies of the Escherichia coli fatty acid synthase (FAS) 
pathway yielded significant information about the structure and dynamics 
of the acyl carrier protein (ACP). Increasing the basic understanding of 
how modular synthases function, interact, and maintain product 
specificity has been a driving goal; such information is critical to 
engineering de novo modular pathways. Identification of the proteins in 
the pathways is essential, but understanding how they move and interact 
remains an intellectual bottleneck. Using mechanism-based crosslinking, 
the E. coli ACP was trapped in functional interaction with the cognate 
dehydratase protein, FabA. Structures were determined 
crystallographically in collaboration with the Tsai lab at the University of 
California, Irvine and by NMR in collaboration with the Opella lab at the 
University of California, San Diego. Residual Dipolar Couplings from NMR, 
together with Accelerated Molecular Dynamics studies in collaboration 
with the McCammon lab at the University of California, San Diego led to 
the identification of key residues necessary for this protein-protein 
  
 
xxvi 
interaction, and quantification of the ACP’s dynamics both as a free 
protein and during interaction with a partner.  
Furthermore, studies of the actinorhodin polyketide synthase (PKS) 
pathway led to insights into the sequestration and cyclization of 
polyketide intermediates. To prevent unwanted side-reactions of 
polyketide intermediates, geometrically appropriate atom replacement 
mimetic probes were synthesized and loaded onto the actinorhodin ACP. 
Chemical shift perturbations of the protein amide resonances allowed 
monitoring of sequestration, as probes of longer length demonstrated 
larger perturbation of more residues than shorter polyketide probes. 
Additionally, studies of the prodigiosin and pyoluteorin pathways 
give new information about sequestration. Traditional NOE methods were 
employed to solve the solution NMR structure of the pyoluteorin carrier 
protein, PltL, in multiple cargo states. For the first time, sequestration of 
intermediates was observed in a non-ribosomal peptide synthetase (NRPS) 
system. Further studies are underway to determine if sequestration is 
observed in other NRPS systems.  
Finally, a follow-up to the ACP FabA project is in an early manuscript 
stage, detailing the E. coli ACP interaction with another partner, the 
ketosynthase FabB. NMR titration experiments, demonstrating key residues 
in the ACP FabB interaction are reported. In vivo complementation of the 
  
 
xxvii 
wt ACP with mutated ACPs showed that perturbing the ACP FabB 
interaction reduces E. coli’s ability to produce unsaturated fatty acids at 
lower temperatures, connecting in vivo observations to in vitro effects. 
While challenges and unknowns remain, the work of this dissertation 
provides significant progress towards the possibilities of engineering novel 
pathways to produce pharmaceutically relevant or biochemically 
valuable products. 
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Chapter 7. Studies of the functional AcpP-FabB interaction both in vitro 
and in vivo 
 
Section 7.1 Introduction 
The dynamic acyl carrier protein (ACP) shuttles the growing fatty 
acid chain between reaction partners of the fatty acid synthase (FAS), 
facilitating fatty acid biosynthesis.1 Protein-protein interactions between 
the ACP and reaction partners must be well characterized for any 
attempts at engineering the FAS to be successful. In our previous work 
reported in chapter four of this dissertation, we employed a mechanism-
based probe to facilitate covalent crosslinking of the E. coli ACP, AcpP, 
with its cognate β-hydroxyl-ACP dehydratase, FabA,2 to trap the transient 
interaction for study. Significant insights into the “chain-flipping” 
mechanism3,4 of substrate delivery were obtained.  
This chapter discusses studies of AcpP with its β-ketoacyl-ACP-
synthase, FabB. FabB is necessary for the production of unsaturated fatty 
acids in E. coli.5 Unline many organisms which produce unsaturated fatty 
acids from saturated fatty acids using oxidases, E. coli produces 
unsaturated fatty acids directly using an alternative pair of ketosynthase 
and dehydratase proteins (Figure 7.1). NMR titration studies were used to 
study the transient interaction in solution. In vivo complementation studies 
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were used to examine the biological effects of mutating residues on the 
AcpP to disrupt the AcpP FabB interaction, with analysis of the fatty acid 
profiles of a key mutant at different temperatures. This work connects in 
vitro structural observations with in vivo complementation studies, laying 
the groundwork for additional engineering of the FAS and providing 
important information about pathways important for infectious disease, 
cancer, and obesity. 
 
Figure 7.1 Unsaturated fatty acid production in E. coli. Saturated fatty acids are 
produced using FabF and FabZ at left. Unsaturations are incorporated and preserved 
using FabA and FabB as demonstrated at right. 
 
Section 7.2 Methods 
Plasmid preparation and transformation for in vivo complementation 
A pMAL-c5x (New England Biolabs) plasmid containing a codon-
optimized wild type AcpP was ordered from GenScript, utilizing the MfeI 
and BamHI restriction sites to remove the Maltose Binding Protein (MBP) 
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and allow expression of tagless AcpP. A leader sequence was required, to 
reinstall the ribosome binding site positioned between MfeI and the MBP 
sequence. This wild type construct was subsequently modified using site-
directed mutagenesis (SDM)6 to produce the mutant library. Primers used 
for SDM are reported in supplementary table S7.1. AcpP constructs were 
transformed into DH5α E. coli cells and plated on Lysogeny Broth, Miller 
(LB) agar plates supplemented with 100 µg/mL ampicillin (Amp). Colonies 
were selected for sequence confirmation and DNA extraction. 
In vivo complementation studies were performed using an AcpP 
complementation cell type developed by Cronan and coworkers; 
CY1877.7 AcpP is an essential protein, and in these cells the genomic 
AcpP has been replaced by a chloramphenicol resistance cassette. 
Native AcpP is then provided by an Ara controlled plasmid under 
spectinomycin (Spec) selection. 
Sequence-confirmed AcpP constructs were transformed into 
chemically competent CY1877 cells produced using standard Rubidium 
chloride competency protocols8. Transformants were plated on LB-agar 
plates supplemented with 100 µg/mL Amp, 50 µg/mL Spec, and 0.2% Ara. 
Colonies were selected and glycerol stocks were prepared and stored at 
-80 OC. 
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Mutant AcpPs were transformed into these cells, carried by the 
pMAL derived constructs described above, under lactose control and 
Amp selection. Production of mutant AcpPs is triggered by providing 
isopropyl β-D-1-thiogalactopyranoside (IPTG) in lieu of Ara. These dense 
overnight cultures were plated as both streaks and lawns on LB-agar 
plates supplemented with 100 µg/mL Amp, 50 µg/mL Spec, 0.2% glucose 
(Glu), and 50 µM IPTG. Cells that could survive on the supplemented AcpP 
construct were positive for complementation. Four mutants could not 
complement, producing no colonies on these plates. These mutants were 
reported in supplementary table S7.1. 
Carrier proteins are expressed in an inactive apo-AcpP form which 
must be post translationally modified with a prosthetic arm, forming holo-
AcpP to be active. In E. coli, this is a function of AcpS, described in 
chapters one and two of this dissertation. AcpP runs as a double band on 
conformationally sensitive urea-Polyacrylamide Gel Electrophoresis (Urea-
PAGE) gels, representing the apo- and holo- forms.  
To confirm production and check for AcpS activity on the mutant 
strains, 5 mL LB cultures supplemented with 100 µg/mL Amp were 
inoculated with transformed DH5α strains and grown overnight. 25 µL of 
dense overnight cultures were used to inoculate fresh cultures in the 
morning. After 4 h, IPTG was added to a final concentration of 1 mM. The 
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cells were allowed to express for 4 h, then harvested by gentle 
centrifugation at 500 RCF. Cells were lysed by sonication in the presence 
of lysozyme, DNase, and RNase. Crude lysates were analyzed by Urea-
PAGE (20% polyacrylamide, 1 M Urea). The presence of two over-
expressed bands on the Urea gels suggests AcpS activity on the mutant 
AcpP yielding a mixture of apo-AcpP and holo-AcpP. 
Reported mutants that could  not complement wild type AcpP in 
CY1877 cells produced only one overexpressed band under such analysis, 
suggesting their inability to complement was due to a lack of AcpS 
activity on the mutants (Figure S7.1). 
 
Fatty acid extraction and analysis 
Constructs that were capable of complementation were subjected 
to fatty acid analysis. 5 mL LB cultures supplemented with 100 µg/mL Amp, 
50 µg/mL Spec, and 0.2% Ara were grown overnight. 10 µL of these dense 
cultures were transferred to fresh LB supplemented with 100 µg/mL Amp, 
50 µg/mL Spec, 0.2% Glu, and 50 µM IPTG. These cultures were allowed to 
grow for 8 h then harvested by gentle centrifugation at 500 RCF, with 
extra care taken to remove as much media as possible. Biological 
replicates of each construct were grown.  
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Fatty acids were extracted as fatty acid methyl esters. To the dry 
cell pellets, 25 µL of 250 µg / mL internal standard of C19 fatty acid methyl 
ester in hexanes, 1 mL of 1 M Hydrochloric acid in Methanol was added 
and the sample was incubated at 65 C for 1 h, vortexing every 15 min. 
After cooling, 1 mL of HPLC grade hexanes was added. To ensure 
maximum extraction, the samples were vortexed for 30 seconds then spun 
down again. The hexanes layer was subjected to GCMS analysis on an 
Agilent 7890A GC and an Agilent 5975C MS system. 
Reference standards were prepared to confirm peak identities 
using retention times. Data was processed for each mutant, and plotted 
as relative abundance for the major fatty acids produced by E. coli. 
 
Protein Preparation for NMR 
 NMR experiments were carried out on 2H, 15N labelled AcpP and 
unlabeled FabB. Wild type AcpP and D38A AcpP were expressed as a His-
tagged constructs via pET vectors. BL21 (DE3) E. coli cells were grown in 
M9 minimal media supplemented with 1 g 15N-NH4Cl and D2O. All growth 
and expression was carried out at 37 OC, with 100 µg / mL Amp or 50 
µg/mL kanamycin (Kan) as appropriate. 
Deuterium acclimation was carried out by first inoculating 5 mL M9 
cultures supplemented with 10% D2O. These cultures were grown 
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overnight and then used to inoculate 5 mL M9 cultures with 25% D2O. In 
turn, these were used to inoculate 50% D2O, then 75%, then 99% D2O. Two 
5 mL overnight M9 cultures supplemented with 99% D2O were spun down 
by gentle centrifugation then resuspended in 1 mL fresh 100% D2O M9 
media, which was then used to inoculate 1 L 15N, 100% D2O M9. At an 
OD600 of 0.9, expression was induced by the addition of 230 mg of IPTG. 
The cells were allowed to express for 4 h, then harvested by 
centrifugation. Labelled proteins were prepped using standard Ni-NTA 
affinity methods. 
 2H, 15N labelled carrier proteins were converted to uniformly apo-
AcpP samples by overnight exposure at 37 OC to AcpH attached to Affi-
10 resin (Bio-Rad), in 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) pH 7.4, 150 mM NaCl, 10% glycerol, 2 mM dithiothreitol (DTT), 
1 mM MnCl2, 15 mM MgCl2, and 0.01% NaN3.9,10 The reaction was 
monitored by Urea-PAGE analysis (20% Polyacrylamide, 1 M Urea).  
 Conversion of apo-AcpP to C8-AcpP was achieved using 
chemoenzymatic means previously developed in the Burkart lab11, and 
an eight-carbon acylated pantetheine mimic bearing amide 
replacement of the native thioester. 
All proteins were purified by fast protein liquid chromatography, 
using Sephadex S-75, Sephadex S-100, and Sephadex S-200 columns, into 
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50 mM KPi pH 7.4. NMR samples were prepared in 45 mM KPi 7.4, 10% D2O, 
5 mM tris(2-carboxyethyl)phosphine (TCEP), and 0.1% NaN3. 
 
NMR Methods and Analysis 
 15N-HSQC NMR titration experiments were acquired with 2H 15N 
labelled AcpP in the presence of varying equivalents of FabB. Peak 
migrations were observed as the relative concentration of FabB 
increased. Titration experiments against FabB were acquired for holo-
AcpP and C8-AcpP, as well as D38A C8-AcpP. Peak migrations were 
quantified by comparing peak positions at the titration endpoints, and 
using the Chemical Shift Perturbation (CSP) formula CSP = 
(0.5*((0.2*deltaN)2+(deltaH)2))^(1/2).12,13 To maintain a constant 
concentration of AcpP and varied the amounts of FabB, for each titration 
set a zero point and a final point were prepared. After NMR acquisition, 
these tubes were mixed incrementally to obtain spectra of the 
intermediate ratios. 
 C8-AcpP vs FabB and C8-AcpP (D38A) vs FabB titration experiments 
were carried out on a Bruker Avance 600 MHz system equipped with a 
cryo-probe. Holo-AcpP vs FabB was carried out on a Varian 800 MHz 
system equipped with a cryo-probe. All spectra used TROSY selection, 
samples were held at 37 OC during acquisition, and recycle delays of 1.5 s 
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at 600 MHz and 1.6 s at 800 MHz were employed. Titration sets were 
planned to include 0.0, 0.5, 1.0, 1.5, and 2.0 equivalents of FabB to AcpP 
to help ensure that the AcpP can be saturated by FabB. 
 
Section 7.3 Results and Discussion 
Solution-state protein NMR experiments 
Solution-state protein NMR experiments were performed to study 
the AcpP FabB interaction. 15N-HSQC titration experiments were 
performed (Figure 7.2). In these experiments, an octanoyl acyl-AcpP was 
exposed to increasing proportions of FabB. Observed peak shifts due to 
the acyl-AcpP FabB interaction differed from observations in the AcpP 
FabA interaction2. D35 and D38 exhibit dramatic chemical shift 
perturbations (CSPs) upon interaction, as well as E47 demonstrating a 
moderate CSP. Overall, the NMR CSP plots suggest the transient 
interaction between AcpP and FabB depends significantly on helix II, and 
to a lesser extent on helix III as well (Figure 7.2 c). 
 Due to the observed importance of D38, a D38A mutant was 
prepared and subjected to the same NMR titration study as the wild type 
AcpP (Figure 7.2). D35A was not selected to avoid perturbing the DSL 
motif necessary for covalent attachment of the prosthetic arm. As 
demonstrated in Figure 7.2 B and C, the D38A mutant is still observed to 
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interact with the FabB. Almost all CSPs observed are smaller, though, 
suggesting the interaction is more transient than the wild type interaction 
with FabB. Additionally, the top of helix II appears to interact more weakly 
in the D38A mutant than in the wild type. 
 
Figure 7.2 NMR titration experiments. 15N, 2H AcpP titrated against unlabeled FabB. A) 
wild-type C8-AcpP titrated against FabB at left, and D38A C8-AcpP titrated against FabB 
at right. B) CSP plot, quantifying the peak migrationgs observed in A. C) Heat-map plot 
of the CSPs observed to demonstrate interaction face. 
 
In vivo studies of the AcpP FabB Interaction 
 Additional in vivo studies of the AcpP FabB interaction were carried 
out by complementation assay, where mutant AcpPs are used to rescue 
AcpP knockout cells. AcpP alanine mutants were observed to have only 
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moderate effect on the fatty acid unsaturation percentages when grown 
at 37 C. (Figure 7.3). However, D38A AcpP mutant was observed to 
produce smaller amounts of unsaturated fatty acids at lower 
temperatures than wild type AcpP (Figure 7.4). 
 
Figure 7.3 Fractional fatty acid profiles produced by mutant AcpP complementation 
experiments. 
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Figure 7.4 Fractional fatty acid profiles produced by wt and D38A AcpP 
complementation experiments at multiple growth temperatures. A) Fatty acid profiles at 
17, 25, and 37 C. B) Overall unsaturation percentage observed. 
 
Section 7.4 Conclusions 
 E. coli maintains viability at lower temperatures by increasing the 
membrane fluidity.5 This is achieved by increasing the proportion of 
unsaturated fatty acids at lower temperatures. The AcpP FabB interaction 
is necessary for processivity and production of these unsaturated fatty 
acids.  
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NMR titration experiments revealed key residues in this interaction. 
These were explored by alanine mutations. Fatty acid profiles were 
obtained by complementation assay and fatty acid analysis. While only 
minimal changes to the fatty acid profile were observed at high 
temperature, at low temperature the D38A mutant failed to produce as 
much unsaturated fatty acids as the wild type AcpP (Figure 7.4). Together, 
these experiments connected in vitro observations with in vivo effects. 
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Section 7.5 Supplementary Information 
Table S7.1 pMAL-c5x constructs for AcpP complementation studies 
Mutant Complement 
viability 
SDM primer forward 
(5’  3’) 
SDM primer reverse  
(5’  3’) 
wt Yes N/A N/A 
S36A No TGATGCTCTGGACAC
CGTGGAACTGGTTAT
GGCGC 
GGTGTCCAGAGCAT
CAGCGCCCAGGTCT
TCCAC 
D35A No GCTGCTTCTCTGGAC
ACCGTGGAACTGGTT
ATGGC 
TGTCCAGAGAAGCA
GCGCCCAGGTCTTC
CACAAAG 
D38A Yes CTCTGGCCACCGTG
GAACTGGTTATGGCG
CTGG 
CACGGTGGCCAGA
GAATCAGCGCCCA
GGTCTTC 
E41A Yes CGTGGCACTGGTTAT
GGCGCTGGAAGAA
GAATTTGATAC 
CATAACCAGTGCCA
CGGTGTCCAGAGAA
TCAGCGC 
E47A No GGCGCTGGCAGAA
GAATTTGATACGGAA
ATTCCGGACG 
TCTTCTGCCAGCGCC
ATAACCAGTTCCACG
GTGTCC 
E48A Yes GGCGCTGGAAGCA
GAATTTGATACGGAA
ATTCCGGACG 
TCTGCTTCCAGCGCC
ATAACCAGTTCCACG
GTGTCC 
I54A No ACGGAAGCTCCGG
ACGAAGAAGCCGA
AAAAATCACCAC 
GTCCGGAGCTTCCGT
ATCAAATTCTTCTTCCA
GCGCC 
D56A Yes ATTCCGGCCGAAGA
AGCCGAAAAAATCA
CCACGGTTC 
CTTCTTCGGCCGGAA
TTTCCGTATCAAATTCT
TCTTCCAG 
E60A Yes GCCGCAAAAATCAC
CACGGTTCAGGCGG
CCATTGAC 
GTGGTGATTTTTGCGG
CTTCTTCGTCCGGAAT
TTCCGTAT 
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Figure S7.1 AcpS activity check on mutant AcpPs. A double band reflects AcpS activity, 
yielding an apo-, holo-AcpP mixture. Mutants denoted in black are viable complements 
to wild type AcpP. Mutants denoted in red are not viable complements. 
 
 
 
Figure S7.2 Representative GCMS trace used in Fatty Acid Methyl Ester analysis and 
quantification. Key Fatty Acid peaks are labeled. Fatty acids were quantified using peak 
areas. 
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